Today’s Top Biotech Stories: Mallinckrodt, Regeneron, Arena, and Omeros

Mallinckrodt, Regeneron, Arena, and Omeros could all loom large in health care headlines this morning. Here’s why.

Feb 11, 2014 at 9:00AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! Let's take a closer look at Mallinckrodt (NYSE:MNK), Regeneron (NASDAQ:REGN), and Arena Pharmaceuticals (NASDAQ:ARNA), and Omeros (NASDAQ: OMER)-- all of which could loom large in health care headlines this morning.

Mallinckrodt buys Cadence Pharmaceuticals for $1.21 billion
First and foremost, health care products company Mallinckrodt just announced its acquisition of Cadence Pharmaceuticals (NASDAQ:CADX) for approximately $1.3 billion in cash to boost its specialty pharmaceuticals segment. Mallinckrodt will pay $14 per share for Cadence, a 27% premium to the company's closing price of $11.07 on Monday. Both companies' boards have unanimously approved the deal.

Cadence is best known for the intravenous painkiller and fever reducer Ofirmev, which the company estimates generated $110.5 million in revenue during the 2013 calendar year. Mallinckrodt reported $2.2 billion in revenues in fiscal 2013. Mallinckrodt expects the acquisition to immediately become earnings accretive in fiscal 2014, and significantly boost its adjusted earnings per share in fiscal 2015. The deal is expected to close in mid to late March.

Regeneron's 2013 revenue and earnings respectively surge 53% and 75%
Meanwhile, Regeneron reported its fourth quarter and full year earnings this morning. U.S. sales of the eye treatment Eylea, which accounted for 66% of Regeneron's full year revenue, rose 46% year-over-year to $402 million for the fourth quarter, and finished fiscal 2013 with $1.41 billion in sales -- a 68% jump from fiscal 2012.

The drug, which is currently approved for Wet AMD (age-related macular degeneration) and macular edema following CRVO (central retinal rein occlusion), primarily competes against Novartis' Lucentis and Roche's Avastin (off-label use). Yesterday, Regeneron announced that its phase 3 VISTA trial for Eylea as a DME (diabetic macular edema) treatment was progressing well. If approved for DME and other indications, analysts believe sales of Eylea could eventually hit $4 billion.

Looking ahead into fiscal 2014, Regeneron expects Eylea's U.S. sales to come in between $1.7 billion to $1.8 billion, representing year-over-year growth between 21% and 28%. In international markets (excluding Japan), Regeneron and Bayer share half of the profits and losses. In Japan, Regeneron receives a royalty on net sales. Overseas sales of Eylea came in at $472 million for 2013.

Eylea's fourth quarter revenue rose 47% to $610 million, while its full year revenue jumped 53% to $2.1 billion. The company's non-GAAP adjusted earnings per share rose 52% year-over-year to $2.24 per share, while its full-year non-GAAP adjusted earnings per share climbed 75% to $8.17 per share.

In other words, Regeneron is firing on all cylinders, and its partnership with Sanofi in alirocumab (cholesterol), sarilumab (rheumatoid arthritis), and other monoclonal antibodies could eventually yield blockbusters which would reduce the weight of Eylea on Regeneron's top line. Regeneron has rallied more than 80% over the past 12 months on optimism regarding Eylea sales and its shared pipeline with Sanofi, and its earnings suggest that the bullish trend could continue.

Will a new agreement with CVS Caremark boost sales of Arena's Belviq?
Arena and its partner Eisai announced yesterday that their obesity drug Belviq will reach more patients thanks to a new agreement with PBM (pharmacy benefits manager) CVS Caremark. The announcement caused shares of Arena to jump more than 7% yesterday, and that rally could continue today.

Arena and Eisai claim that the agreement will allow the drug to reach over half of all Americans. Sales of Arena's Belviq and its competitor, VIVUS' Qsymia, have both been painfully slow over the past year:



2Q product sales

3Q product sales

Peak sales estimate



$1.3 million

(31.5% of Eisai's sales of $4.1 million)

$1.7 million

(31.5% of Eisai's sales of $5.4 million)

$1.0 billion



$5.5 million

$6.4 million

$1.8 billion

Source: Quarterly earnings reports. Note: Eisai markets Belviq globally, except in South Korea, Taiwan, Australia, New Zealand, and Israel.

Both companies have been giving away free samples to establish a patient base, but I believe that sales will remain in the single-digit millions for some time, a far cry from the blockbuster sales that some on Wall Street had expected. Investors should also note that health insurer Aetna is currently studying both Belviq and Qsymia in a pilot program which could also boost sales for both companies.

More good news for Omeros' OMS824
Last but not least, Omeros just announced additional positive phase 1 data for OMS824, its lead compound in the company's PDE10 (phosphodiesterase 10) program. OMS824 inhibits the production of PDE10, an enzyme implicated in brain diseases such as Huntington's disease and schizophrenia. If approved, analysts believe OMS824 could generate peak sales of $1 billion -- a huge boost for a company with no marketed products and only $1.4 million in revenues over the first nine months of fiscal 2013.

The phase 1 data shows a 70% engagement of PDE10 without evidence of extrapyramidal symptoms (EPS). An average of 66% occupancy at PDE10 was observed at the striatum, the part of the brain which plays a crucial role in cognition. The drug was reported to be "well tolerated" with the primary side effect being drowsiness.

Investors should note that this is the second bit of good news about OMS824 that Omeros has recently released. At the end of January, Omeros reported positive phase 2a results from a clinical trial of OMS824, which showed that the drug was well tolerated with limited side effects in a group of 33 patients.

OMS824 isn't Omeros' most advanced drug candidate. OMS302, a treatment for ophthalmological procedures, and OMS103HP, a treatment for arthroscopy and menisectomy procedures, are both closer to market approvals. Combined, the two drugs are expected to generate peak sales of just over $1 billion. Shares of Omeros have rallied more than 110% over the past 12 months on optimism regarding these three main drug candidates.

Another top stock to watch this morning...
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers